Cargando…

Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: A Systematic Review and Meta-Analysis

OBJECTIVE: This meta-analysis aimed to comprehensively examine the relationship between the clinicopathological and demographical characteristics and ALK rearrangements in patients with non-small cell lung cancer (NSCLC). METHODS AND MAIN FINDINGS: In total, 62 qualified articles including 1178 ALK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Liang, Feng, Yun, Wan, Huanying, Shi, Guochao, Niu, Wenquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069179/ https://www.ncbi.nlm.nih.gov/pubmed/24959902 http://dx.doi.org/10.1371/journal.pone.0100866

Ejemplares similares

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
por: Cognigni, Valeria, et al.
Publicado: (2022)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Zhang, Huan, et al.
Publicado: (2021)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement
por: Hou, Xiaoming, et al.
Publicado: (2023)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR
por: Li, Yuan, et al.
Publicado: (2013)

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer
por: Lee, Kyung Ann, et al.
Publicado: (2014)

Development of a novel ALK rearrangement screening test for non–small cell lung cancers
por: Chen, Yi-Lin, et al.
Publicado: (2021)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis
por: Zhao, Fengzhi, et al.
Publicado: (2015)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
por: Mattsson, Johanna S. M., et al.
Publicado: (2016)

Cystic brain metastases in ALK-rearranged non-small cell lung cancer
por: Marta, Guilherme Nader, et al.
Publicado: (2018)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
por: Zhao, Ruiying, et al.
Publicado: (2022)

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation
por: Zhang, Bo, et al.
Publicado: (2022)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study
por: Shi, Jinghan, et al.
Publicado: (2020)

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
por: Zhang, Ning-Ning, et al.
Publicado: (2014)

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
por: Lee, Boram, et al.
Publicado: (2016)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
por: Li, Pupu, et al.
Publicado: (2019)

ALK-rearrangements and testing methods in non-small cell lung cancer: a review
por: Shackelford, Rodney E., et al.
Publicado: (2014)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer
por: Wang, Zizong, et al.
Publicado: (2022)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
por: Feng, Junnan, et al.
Publicado: (2022)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_letdkumm6l4m4ceo4a13mki05u